8 results about "Bronchitic asthma" patented technology

The invention discloses a bronchial asthma treatment drug based on RBX1 inhibition and application thereof, and finds that expression of RBX1 in asthma patients and disease models is up-regulated, and the expression level of RBX1 is in positive correlation with airway epithelial barrier injury and active oxygen accumulation degree, which indicates that RBX1 is a key new target for asthma treatment. On the basis of the compound Z226407860 and the compound Z4189742053, the condition that the expression of the RBX1 can be effectively inhibited is further proved. In an in-vitro model, the compounds not only significantly reduce the protein level of RBX1, but also show a good synergistic treatment effect: the compounds can effectively relieve the injury of the airway epithelial barrier and promote the integrity recovery of the barrier, and can inhibit the excessive accumulation of active oxygen at the same time, so that the asthma process is intervened from two correlative core pathological links. The research provides a solid experimental basis and a candidate compound with a clear prospect for developing a therapeutic drug which aims at bronchial asthma and has a brand new action mechanism.

FIELD: pediatrics and pulmonology.SUBSTANCE: used to predict the risk of severe bronchial asthma in children. Anamnesis is collected, blood is taken, and the child's blood is tested in a laboratory. From the anamnesis, the duration of the disease in years and the number of exacerbations over the current 12 months in points are specified. The peak expiratory flow rate is measured using a peak flow meter, %. The concentration of connexin 43 (CX43), ng / ml, is determined in the child’s blood serum at the time of inclusion in the study. The prognosis for the risk of severe bronchial asthma in children P is calculated using the stated formula. If the P value is 0.52 or higher, a high risk of severe bronchial asthma is predicted.EFFECT: method provides the possibility of increasing the accuracy and reliability of the prognosis of the severity of bronchial asthma in children by taking into account the declared clinical symptoms and risk factors for bronchial asthma in children and adolescents of both sexes who do not have signs of a severe course of the disease at the time of examination.1 cl, 4 ex

The present invention relates to the prophylactic and / or therapeutic treatment of a disease selected from the group consisting of long-term COVID disease, myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) disease, fibromyalgia, dementia, neoplastic disease, autoimmune disease, schizophrenia, epileptic seizure disease, excessive inflammatory disease, chronic inflammatory bowel disease, rheumatic disease, obesity, and the like. Hyperuricemia, diabetes (IDDM / NIDDM), acute viral diseases, amyotrophic lateral sclerosis (ALS), bronchial asthma, atopic allergic disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, autoimmune diseases / antibody-related diseases, bipolar affective disorders, celiac disease (CD), chronic obstructive pulmonary disease (COPD), and the like. Chronic inflammatory bowel disease (CED) (i.e. Crohn's disease, ulcerative colitis), cystic fibrosis / cystic fibrosis, depression, endometriosis, polycystic ovarian syndrome, eating disorders, anxiety disorders, addiction disorders, frontotemporal dementia (Pickk's disease), Graves's disease (GD), generalized cardiovascular diseases, Alzheimer's disease, Parkinson's disease, meningitis, multiple sclerosis (MS), and the like. Muscular dystrophy, neurodermatitis, peripheral arterial occlusion disease (PAOD), pneumonia, generalized post-vaccination syndrome and vaccine damage, post-viral infection syndrome, psoriasis, pulmonary arterial hypertension, restless leg syndrome, restrictive pulmonary disease, rheumatoid arthritis (RA), division affective disorder, sepsis, sicca syndrome (SS), scleroderma, and the like. Systemic lupus erythematosus (SLE) and unsatisfactory fertility desires, using an active agent having a nicotinic acetylcholinergic agonist and / or an active agent having a muscarinic acetylcholinergic agonist and / or a muscarinic acetylcholinergic antagonist. This provides a very effective prophylactic and / or therapeutic treatment for these diseases. This prevention or treatment is also readily tolerable, cost effective and easy to apply.

A use of SRT2104 in preparation of a drug for treatment of bronchial asthma is provided, relating to the field of bronchial asthma treatment. The comprehensive analysis of the activation effect of SRT2104 on silent information regulator 1 (SIRT1) in the airway epithelium under asthma conditions and its alleviation effect on asthma airway inflammation is conducted. It is demonstrated that SRT2104 can be activated in the airway epithelium under asthma condition and effectively control asthma airway inflammation. A foundation is laid for the discovery of clinical drug targets and the development of drugs for the treatment of bronchial asthma.

This invention belongs to the field of traditional Chinese medicine composition technology, specifically relating to a traditional Chinese medicine composition and preparation for treating bronchial asthma. The traditional Chinese medicine composition consists of the following raw materials in parts by weight: 9-11 parts Perilla seed, 6-8 parts White mustard seed, 6-8 parts Lepidium seed, 6-8 parts Radish seed, 4-6 parts Scutellaria baicalensis, 9-11 parts Houttuynia cordata, 3-5 parts Prepared Ephedra, 4-6 parts Fresh Fritillaria cirrhosa, 5-7 parts Magnolia officinalis, and 3-5 parts Schisandra chinensis. This invention not only benefits lung qi and promotes proper lung function, but also addresses the issue that impaired lung function can lead to stagnant heat and dampness. Therefore, Scutellaria baicalensis and Houttuynia cordata are used to clear heat, purge fire, and dry dampness. Persistent wheezing inevitably depletes lung qi, damages lung fluids, and harms kidney essence. Therefore, Schisandra chinensis is used to astringe the lungs, nourish the kidneys, generate fluids, and consolidate essence, restoring normal lung function and benefiting both the lungs and kidneys, thus relieving wheezing.

The application discloses a traditional Chinese medicine composition for relieving asthma, which comprises fried ephedra, asarum, inula flower, rhodiola, bitter apricot kernel, euphorbia, lonicera, earthworm, oldenlandia and licorice. The traditional Chinese medicine composition has the characteristics of ascending and descending combination, yin and yang combination, cold and warm combination and treatment of symptoms and root causes, and is suitable for children with asthma caused by latent pathogen, phlegm, blood stasis and air retention. The traditional Chinese medicine composition can improve the lung function, cough, expectoration and other symptoms of the children, effectively reduce the recurrence rate of bronchial asthma of the children with wind-phlegm-latent-lung type, and has no obvious adverse reactions and side effects. The application also protects an oral dose prepared from the traditional Chinese medicine composition and application thereof.

Disclosed herein are compounds useful for the inhibition of STAT6. The compounds have a general Formula (I) or (II) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) and (II) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, diseases / disorders related to the activity of STAT6, such as an allergic disease or an inflammatory disease, including but not limited to atopic dermatitis or bronchial asthma. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I) and (II).

The invention discloses application of a marker in preparation of a kit for diagnosing bronchial asthma or diagnosing and distinguishing bronchial asthma and chronic obstructive pulmonary disease, and belongs to the field of disease detection and diagnosis. The invention discloses a method. 1-palmitoyl-2-glutaryl-sn-glycerol-3-phosphorylcholine, beta-acetyl-gamma-o-alkyl-L-alpha-phosphatidylcholine and (R) Any one or two or all three of the-3-hydroxytetradecanoic acid and the-3-hydroxytetradecanoic acid have the value of diagnosing and distinguishing the chronic obstructive pulmonary disease and the bronchial asthma or diagnosing and distinguishing the bronchial asthma and healthy subjects. Therefore, a diagnostic kit for diagnosing and distinguishing the chronic obstructive pulmonary disease and the bronchial asthma or diagnosing and distinguishing the bronchial asthma can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.